YI Quote, Financials, Valuation and Earnings

CASI Pharmaceuticals, Inc. has a net margin of -0.62% compared to 111, Inc.'s net margin of -353.92%. 111, Inc.'s return on equity of -26.75% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 1488.39%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 325.53%. Given that 111, Inc. has higher upside potential than CASI Pharmaceuticals, Inc., analysts believe 111, Inc. is more attractive than CASI Pharmaceuticals, Inc..

111, Inc. has a beta of 0.484, which suggesting that the stock is 51.601% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

111, Inc. quarterly revenues are $443.2M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. 111, Inc.'s net income of -$2.8M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, 111, Inc.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.02x versus 0.55x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

China Pharma Holdings, Inc. has a net margin of -0.62% compared to 111, Inc.'s net margin of -86.16%. 111, Inc.'s return on equity of -26.75% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 1488.39%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that 111, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe 111, Inc. is more attractive than China Pharma Holdings, Inc..

111, Inc. has a beta of 0.484, which suggesting that the stock is 51.601% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.

111, Inc. quarterly revenues are $443.2M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. 111, Inc.'s net income of -$2.8M is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, 111, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.02x versus 1.45x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech Ltd. has a net margin of -0.62% compared to 111, Inc.'s net margin of --. 111, Inc.'s return on equity of -26.75% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 1488.39%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that 111, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe 111, Inc. is more attractive than Sinovac Biotech Ltd..

111, Inc. has a beta of 0.484, which suggesting that the stock is 51.601% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. 111, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.

111, Inc. quarterly revenues are $443.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. 111, Inc.'s net income of -$2.8M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, 111, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.02x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of -0.62% compared to 111, Inc.'s net margin of -30.98%. 111, Inc.'s return on equity of -26.75% beat Zai Lab Ltd.'s return on equity of -26.7%.

111, Inc. has a consensus price target of --, signalling upside risk potential of 1488.39%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 150.57%. Given that 111, Inc. has higher upside potential than Zai Lab Ltd., analysts believe 111, Inc. is more attractive than Zai Lab Ltd..

111, Inc. has a beta of 0.484, which suggesting that the stock is 51.601% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.

111, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 111, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.

111, Inc. quarterly revenues are $443.2M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. 111, Inc.'s net income of -$2.8M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, 111, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 111, Inc. is 0.02x versus 4.80x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.